Research Papers:
Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1606 views | HTML 1831 views | ?
Abstract
Jun Xie1,2,*, Chuangzhi Zhu2,*, Jianting Wu1,2, Cailing Li2, Liya Luo1, Lingling Xia1, Xianxin Li2, Yaoting Gui2, Zhiming Cai1, Zesong Li1
1Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China
2Peking University Shenzhen Hospital, Shenzhen 518036, China
*These authors have contributed equally to this work
Correspondence to:
Zesong Li, e-mail: [email protected]
Keywords: renal cell cancer (RCC), C12orf59, von Hippel-Lindau (VHL), prognosis, survival
Received: November 06, 2014 Accepted: December 26, 2015 Published: January 07, 2016
ABSTRACT
C12orf59 is newly identified gene in kidney. However, the relation of C12orf59 expression and clinic features is unknown. Here, our study showed that C12orf59 was broadly expressed in normal human tissues with high expression levels in kidney while its expression is beyond detectable in a panel of cancer cell lines. C12orf59 expression in RCC was significantly decreased compared with corresponding adjacent noncancerous tissues (P < 0.01). The decreased C12orf59 expression was correlated with lymph node status (P < 0.05), distant metastases (P < 0.05), poor survival (P < 0.001) (HR 3.00; 95% CI, 1.29–7.53), VHL non-sense mutations or frame-shift mutations (P < 0.01), and UMPP gene non-sense mutations or frame-shift mutations (P = 0.01). Thus, we propose that the decreased C12orf59 expression status is a prognostic biomarker of ccRCC and cooperates with the loss of VHL all the while promoting renal carcinogenesis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6829